Abbott Laboratories EBITDA 2010-2025 | ABT
Abbott Laboratories annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Abbott Laboratories EBITDA for the quarter ending March 31, 2025 was $2.718B, a 4.82% increase year-over-year.
- Abbott Laboratories EBITDA for the twelve months ending March 31, 2025 was $10.043B, a 3.31% increase year-over-year.
- Abbott Laboratories 2024 annual EBITDA was $10.043B, a 3.31% increase from 2023.
- Abbott Laboratories 2023 annual EBITDA was $9.721B, a 16.41% decline from 2022.
- Abbott Laboratories 2022 annual EBITDA was $11.629B, a 2.79% decline from 2021.
| Abbott Laboratories Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $10,043 |
| 2023 | $9,721 |
| 2022 | $11,629 |
| 2021 | $11,963 |
| 2020 | $8,684 |
| 2019 | $7,546 |
| 2018 | $6,960 |
| 2017 | $5,497 |
| 2016 | $4,544 |
| 2015 | $4,339 |
| 2014 | $4,147 |
| 2013 | $3,852 |
| 2012 | $4,142 |
| 2011 | $4,673 |
| 2010 | $8,712 |
| 2009 | $8,325 |
| Abbott Laboratories Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2024-12-31 | $2,718 |
| 2024-09-30 | $2,660 |
| 2024-06-30 | $2,474 |
| 2024-03-31 | $2,191 |
| 2023-12-31 | $2,593 |
| 2023-09-30 | $2,471 |
| 2023-06-30 | $2,342 |
| 2023-03-31 | $2,315 |
| 2022-12-31 | $2,111 |
| 2022-09-30 | $2,585 |
| 2022-06-30 | $3,198 |
| 2022-03-31 | $3,735 |
| 2021-12-31 | $3,261 |
| 2021-09-30 | $3,393 |
| 2021-06-30 | $2,266 |
| 2021-03-31 | $3,043 |
| 2020-12-31 | $3,298 |
| 2020-09-30 | $2,303 |
| 2020-06-30 | $1,497 |
| 2020-03-31 | $1,586 |
| 2019-12-31 | $2,145 |
| 2019-09-30 | $1,952 |
| 2019-06-30 | $1,957 |
| 2019-03-31 | $1,492 |
| 2018-12-31 | $1,928 |
| 2018-09-30 | $1,808 |
| 2018-06-30 | $1,732 |
| 2018-03-31 | $1,492 |
| 2017-12-31 | $1,566 |
| 2017-09-30 | $1,543 |
| 2017-06-30 | $1,464 |
| 2017-03-31 | $924 |
| 2016-12-31 | $1,273 |
| 2016-09-30 | $1,237 |
| 2016-06-30 | $1,163 |
| 2016-03-31 | $871 |
| 2015-12-31 | $1,181 |
| 2015-09-30 | $1,096 |
| 2015-06-30 | $1,081 |
| 2015-03-31 | $981 |
| 2014-12-31 | $1,224 |
| 2014-09-30 | $1,083 |
| 2014-06-30 | $1,077 |
| 2014-03-31 | $763 |
| 2013-12-31 | $844 |
| 2013-09-30 | $909 |
| 2013-06-30 | $1,063 |
| 2013-03-31 | $1,036 |
| 2012-12-31 | $564 |
| 2012-09-30 | $1,070 |
| 2012-06-30 | $1,256 |
| 2012-03-31 | $1,252 |
| 2011-12-31 | $2,731 |
| 2011-09-30 | $1,433 |
| 2011-06-30 | $2,585 |
| 2011-03-31 | $2,047 |
| 2010-12-31 | $2,540 |
| 2010-09-30 | $1,858 |
| 2010-06-30 | $2,281 |
| 2010-03-31 | $2,033 |
| 2009-12-31 | $2,411 |
| 2009-09-30 | $2,180 |
| 2009-06-30 | $2,209 |
| 2009-03-31 | $1,525 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $230.702B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $154.217B | 38.61 |
| Stryker (SYK) | United States | $145.561B | 30.44 |
| EssilorLuxottica (ESLOY) | France | $133.244B | 0.00 |
| Medtronic (MDT) | Ireland | $107.028B | 15.63 |
| Lonza Group Ag (LZAGY) | Switzerland | $52.631B | 0.00 |
| Haleon (HLN) | United Kingdom | $47.943B | 27.26 |
| ResMed (RMD) | United States | $35.287B | 26.50 |
| GE HealthCare Technologies (GEHC) | United States | $31.763B | 15.08 |
| Agilent Technologies (A) | United States | $30.897B | 20.41 |
| Terumo (TRUMY) | Japan | $29.152B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.100B | 17.21 |
| Insulet (PODD) | United States | $18.209B | 77.71 |
| Zimmer Biomet Holdings (ZBH) | United States | $17.901B | 11.50 |
| Baxter (BAX) | United States | $15.608B | 11.66 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.425B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $7.970B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.395B | 18.18 |
| Bio-Rad Laboratories (BIO) | United States | $6.728B | 22.75 |
| Prestige Consumer Healthcare (PBH) | United States | $4.111B | 19.62 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Perrigo (PRGO) | Ireland | $3.444B | 9.86 |
| ICU Medical (ICUI) | United States | $3.347B | 28.51 |
| Haemonetics (HAE) | United States | $3.139B | 14.77 |
| Envista Holdings (NVST) | United States | $2.876B | 23.90 |
| GN Store Nord (GNNDY) | Denmark | $2.071B | 17.15 |
| QuidelOrtho (QDEL) | United States | $1.868B | 15.64 |
| LeMaitre Vascular (LMAT) | United States | $1.817B | 40.63 |
| AtriCure (ATRC) | United States | $1.439B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.359B | 21.40 |
| Neogen (NEOG) | United States | $1.224B | 15.67 |
| AdaptHealth (AHCO) | United States | $1.173B | 11.30 |
| Kestra Medical Technologies (KMTS) | United States | $1.159B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.150B | 0.00 |
| InMode (INMD) | Israel | $0.991B | 9.08 |
| Phibro Animal Health (PAHC) | United States | $0.791B | 12.13 |
| Evolus (EOLS) | United States | $0.774B | 0.00 |
| Owens & Minor (OMI) | United States | $0.632B | 5.38 |
| Curaleaf Holdings (CURLF) | Canada | $0.618B | 0.00 |
| CeriBell (CBLL) | United States | $0.583B | 0.00 |
| Valneva SE (VALN) | France | $0.557B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.539B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.470B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.442B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.437B | 0.00 |
| Omeros (OMER) | United States | $0.397B | 0.00 |
| Surmodics (SRDX) | United States | $0.386B | 0.00 |
| SNDL (SNDL) | Canada | $0.355B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.348B | 15.09 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.312B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.290B | 26.18 |
| Sanara MedTech (SMTI) | United States | $0.288B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.265B | 47.20 |
| Sanuwave Health (SNWV) | United States | $0.265B | 0.00 |
| Cerus (CERS) | United States | $0.249B | 0.00 |
| ZimVie (ZIMV) | United States | $0.247B | 14.80 |
| Canopy Growth (CGC) | Canada | $0.234B | 0.00 |
| Quanterix (QTRX) | United States | $0.225B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.221B | 0.00 |
| High Tide (HITI) | Canada | $0.192B | 0.00 |
| Biote (BTMD) | United States | $0.178B | 4.06 |
| Utah Medical Products (UTMD) | United States | $0.172B | 13.83 |
| TriSalus Life Sciences (TLSI) | United States | $0.165B | 0.00 |
| Brainsway (BWAY) | Israel | $0.164B | 51.24 |
| Organigram Global (OGI) | Canada | $0.149B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.145B | 17.91 |
| Jin Medical (ZJYL) | China | $0.125B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.118B | 0.00 |
| Exagen (XGN) | United States | $0.113B | 0.00 |
| Agape ATP (ATPC) | $0.105B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.103B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.093B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.081B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.61 |
| Veru (VERU) | United States | $0.075B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.057B | 0.00 |
| United Health Products (UEEC) | United States | $0.057B | 0.00 |
| ImmuCell (ICCC) | United States | $0.047B | 0.00 |
| Apyx Medical (APYX) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.041B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.041B | 59.50 |
| Safety Shot (SHOT) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 11.31 |
| Nephros (NEPH) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |